Abstract:Healthcare‐associated infections are acquired by over 4% of hospital admissions and result in approximately $28 to $45 billion US dollars of direct hospital costs. In addition, the increased incidence of antibiotic resistance highlights the necessity to develop more effective methods of prevention and/or treatment of bacterial infection. Previous work has shown that exposure of mice to lipopolysaccharide (LPS), which mimics a bacterial infection, results in an elevation in plasma pro‐inflammatory cytokines and activation of the toll‐like receptor 4 (TLR4). Recently, it has also been demonstrated that prior exposure to a TLR4 agonist attenuated plasma pro‐inflammatory cytokine response to LPS and improved survival (i.e. endotoxin tolerance). One such TLR4 agonist is monophosphoryl lipid A (MPLA), an adjuvant designed based on the structure of LPS. When MPLA is given prior to or at the time of infection, there is not only a reduced mortality as the result of the infection but there is also a reduction in the plasma pro‐inflammatory cytokine levels compared to a vehicle prime. These investigations also revealed that prior treatment of MPLA altered the metabolic phenotype of bone‐marrow‐derived macrophages. These macrophages have elevated glycolysis, oxidative capacity, and ATP production. Infection is also associated with hyperglycemia and systemic insulin resistance and proinflammatory cytokines are thought to contribute to the insulin resistance. Thus, we hypothesized that systemic administration of MPLA would also result in improved systemic metabolism and insulin sensitivity. To test this hypothesis, we performed hyperinsulinemic (2 mU·kg−1·min−1), euglycemic clamps on chronically catheterized (carotid artery and jugular vein) wild‐type mice. Three days after catheterization, mice are injected intraperitoneally with MPLA (20 mg) or saline vehicle for 2 days. On day 5 all animals received LPS (2μg/g) and clamps were performed. 3‐3Hglucose and 14C‐2deoxyglucose were infused to assess whole body glucose flux and tissue specific glucose uptake, respectively. Administration of LPS resulted in impaired (~35%) insulin sensitivity in saline group relative to historical controls; as reflected in the decrease in glucose infusion rate (Figure 1). Surprisingly, we demonstrated that mice given MPLA injections had a further impairment in insulin sensitivity compared to saline treated mice in the presence of equivalent increases in insulin levels (Figure 2). This was reflected as decreases in glucose uptake (Rg) in multiple tissues (Figure 3), while insulin suppression of endogenous glucose production was similar. Overall, these data suggest that despite beneficial metabolic changes that occur in bone‐marrow derived macrophages upon exposure to MPLA, prior treatment with MPLA does not protect against LPS‐induced insulin resistance. In fact, MPLA amplifies the insulin resistance in LPS‐treated mice. In summary, the immunological protection conferred by the MPLA shown in previous studies did not protect the mice from the systemic insulin resistance. Therefore, therapies developed to combat bacterial infection may provide immunological protection for the patient without protecting from the comorbidity of hyperglycemia. The impact of pretreatment with MPLA or saline on glucose infusion rates (Figure 1); plasma insulin levels (Figure 2); and tissue glucose uptake (Figure 3) in mice after a LPS challenge. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

The extracellular domain of Staphylococcus aureus LtaS binds insulin and induces insulin resistance during infection

Periodontitis As a Novel Contributor of Adipose Tissue Inflammation Promotes Insulin Resistance in a Rat Model

The attenuation of Th1 and Th17 responses via autophagy protects against methicillin-resistant <i>Staphylococcus aureus</i>-induced sepsis

A Distinct Role of STING in Regulating Glucose Homeostasis Through Insulin Sensitivity and Insulin Secretion.

Extracellular fibrinogen-binding protein released by intracellular Staphylococcus aureus suppresses host immunity by targeting TRAF3

GlmS plays a key role in the virulence factor expression and biofilm formation ability of Staphylococcus aureus promoted by advanced glycation end products

Diabetes mellitus promotes the nasal colonization of high virulent Staphylococcus aureus through the regulation of SaeRS two-component system

MAE4, an eLtaS monoclonal antibody, blocks Staphylococcus aureus virulence

The Tst Gene Associated Staphylococcus Aureus Pathogenicity Island Facilitates Its Pathogenesis by Promoting the Secretion of Inflammatory Cytokines and Inducing Immune Suppression.

Influence of Transcription Regulator SAUSA300_1968 on the Virulence Protein Secretion and Immune Evasion by Staphylococcus Aureus.

MPLA‐induced endotoxin tolerance does not protect against LPS insulin resistance

Inflammasome-mediated glucose limitation induces antibiotic tolerance in Staphylococcus aureus

Staphylococcus aureus Conquers Host by Hijacking Mitochondria via PFKFB3 in Epithelial Cells

Metabolic Sensor Governing Bacterial Virulence in Staphylococcus Aureus

Post-translational toxin modification by lactate controls Staphylococcus aureus virulence

Type VII secretion system extracellular protein B targets STING to evade host anti- Staphylococcus aureus immunity

The effect of immunoregulation of Streptococcus lactis L16 strain upon Staphylococcus aureus infection

Bacterial Endotoxin Stimulates Adipose Lipolysis Via Toll-Like Receptor 4 and Extracellular Signal-regulated Kinase Pathway

Metabolic Endotoxemia Initiates Obesity and Insulin Resistance

Diabetes mellitus promotes the nasal colonization of high virulent Staphylococcus aureus through the regulation of SaeRS two-component systemnasal colonized S. aureus in type 2 diabetes.

TLR4 sensing of IsdB of Staphylococcus aureus induces a proinflammatory cytokine response via the NLRP3-caspase-1 inflammasome cascade